BioStacks

Fatty Acid

Palmitoleic Acid (Omega-7)

Evidence

Limited
Evidence: 2 of 5 (Limited)

What the evidence says

Palmitoleic acid (16:1 n-7) is a monounsaturated omega-7 fatty acid; Provinal is a purified (macadamia/fish-derived) branded form. A few small short RCTs suggest reductions in CRP, triglycerides and LDL and a modest HDL rise at ~210 mg/day, and a 12-week RCT reported skin-barrier improvement.

A few small, short, partly industry-linked RCTs; mixed results and one withdrawn paper.

Top Palmitoleic Acid (Omega-7) supplements

About Palmitoleic Acid (Omega-7)

Palmitoleic acid (16:1 n-7) is a monounsaturated omega-7 fatty acid; Provinal is a purified (macadamia/fish-derived) branded form. A few small short RCTs suggest reductions in CRP, triglycerides and LDL and a modest HDL rise at ~210 mg/day, and a 12-week RCT reported skin-barrier improvement. However the evidence base is thin, short, sometimes industry-linked, and mixed (a mixed omega-7 supplement at ~688 mg/day showed no anti-inflammatory effect, and one lipid RCT was formally withdrawn). Grades low pending larger independent replication.

What Palmitoleic Acid (Omega-7) supports

  • Small short-term trials suggest modest improvements in triglycerides and LDL, though results are inconsistent and unreplicated at scale
  • One 12-week RCT reported improved skin barrier hydration, from a single study

How much Palmitoleic Acid (Omega-7) to take

The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.

Effective

210500

mg

Small trials used ~210 mg/day palmitoleic acid (as 420 mg Provinal) up to 500 mg/day for 12 weeks. Doses are study-derived, not an established therapeutic standard.

Clinical evidence

Limited clinical evidence. A few small, short, partly industry-linked RCTs; mixed results and one withdrawn paper.

NIH Fact Sheet